[Alpha Tau in PR Newswire] Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™

JERUSALEM, June 8, 2021 /PRNewswire/ — Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM is pleased to announce that it has received a Breakthrough Device Designation for Alpha DaRT from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of Squamous Cell Carcinoma of the skin and oral cavity without curative standard of care.

Read more here.